Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01927913
Other study ID # SPD602-204
Secondary ID FBS0701 (SSP-004
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date November 20, 2014
Est. completion date October 30, 2015

Study information

Verified date May 2021
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this open-label study is to assess liver iron concentration using MRI imaging in subjects with beta-thalassemia when administered with either SPD602 or deferasirox for the treatment of chronic transfusional iron overload.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date October 30, 2015
Est. primary completion date October 30, 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: These criteria are to be met at the Screening Visit (Visit 1), the Washout Visit (Visit 2), and the Baseline Visit (Visit 3), if reassessed. - An understanding, ability, and willingness to fully comply with study procedures and restrictions. - Ability to voluntarily provide written, signed, and dated (personally or via a legally authorized representative) informed consent as applicable to participate in the study before completing any study-related procedures. - Subjects 18 years of age or older at the time of signing consent. - Female subjects should be one of the following: 1. Post-menopausal (12 consecutive months of spontaneous amenorrhea) 2. Surgically sterile, or 3. Females of child-bearing potential must have a negative serum Beta-HCG pregnancy test at the Screening Visit (Visit 1) and a negative urine pregnancy test at the Baseline Visit (Visit 3). Females of child-bearing potential must agree to abstain from sexual activity that could result in pregnancy or agree to use acceptable methods of contraception. - Subjects with beta-thalassemia who have received at least 100mL/kg of packed red blood cells (or >20 transfusion units) and who have iron overload (transfusional hemosiderosis) requiring chronic treatment with an iron chelator. - Serum ferritin >500µg/L at the Screening Visit (Visit 1). - Baseline LIC (last MRI assessment prior to Day 1) greater than or equal to 2.0mg and less than 30.0mg iron per g (equivalent dry weight, liver) determined by FerriScan® R2 MRI. 8. Mean of the previous 3 pre-transfusion hemoglobin concentrations greater than or equal to 7.5g/dL assessed at the Screening Visit (Visit 1) (1 value from clinical laboratory tests taken at the Screening Visit [Visit 1] and the previous 2 historical values available). Exclusion Criteria: - Severe iron overload including: (a) cardiac T2* MRI less than 10.0ms; or (b) LIC by FerriScan® R2 MRI greater than or equal to 30.0mg/g liver (dw) as assessed at the Screening Visit (Visit 1). - Iron overload from causes other than transfusional siderosis. - Subjects with thalassemia intermedia - Unable to undergo MRI assessment. - Cardiac LVEF less than 50% at baseline testing by MRI. - Subjects with documented liver failure (presence of portal hypertension, hepatic edema, ascites, cirrhosis), Child-Pugh C hepatic impairment, or biliary disorder. - Platelet count <100 x 109/L at the Screening Visit (Visit 1). - Absolute neutrophils counts of <1500mm3 at the Screening Visit (Visit 1). - Evidence of renal insufficiency eg, creatinine clearance <60mL/min or serum creatinine >1.5x ULN at the Screening Visit (Visit 1). - Clinically significant laboratory assessments at the Screening Visit (Visit 1). - Significant proteinuria: urinary protein/creatinine ratio >1.0 in a non-first void urine sample at the Screening Visit (Visit 1). - Current or recurrent disease that could affect the action, absorption, or disposition of the investigational product, or clinical or laboratory assessments. - Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition, including pregnancy, that presents undue risk from the investigational product or procedures. - Current use of any medication contraindicated in the deferasirox prescribing information/SmPC. - Known or suspected intolerance or hypersensitivity to SSP-004184AQ, deferasirox, closely-related compounds, or any of the stated ingredients in either medication. - Known history of alcohol or other substance abuse within the last year. - Within 30 days prior to the Baseline Visit (Visit 3): 1. Have used an investigational product 2. Have been enrolled in a clinical study (including vaccine studies) that, in the investigator's opinion, may impact this study. - History of malignancy within the past 5 years, with the exception of basal cell or squamous cell skin carcinoma or cervical carcinoma in situ or completely resected colon carcinoma in situ. - Insufficient venous access that precludes prescribed blood draws for safety laboratory assessments. - Pregnant or lactating females.

Study Design


Intervention

Drug:
SPD602
32, 50 or 75 mg/kg/day BID, capsule
Deferasirox
Per approved country specific label

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Shire

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Liver Iron Concentration (LIC) from Baseline Utilizing R2 Magnetic Resonance Imaging (MRI) 48 Weeks
Secondary Response Rate Utilizing R2* MRI 48 weeks
Secondary Change in Cardiac Iron Concentration (CIC) from baseline Utilizing T2* MRI 48 weeks
Secondary Change in Serum Ferritin Levels from Baseline 48 weeks
Secondary Change in Pancreas Iron Concentration (PIC) from Baseline Utilizing R2* MRI 48 weeks
Secondary Left Ventricular Ejection Fraction (LVEF) Utilizing MRI 48 weeks
Secondary Gastrointestinal Symptom Rating Scale 48 weeks
Secondary Total Neuropathy Score nurse (TNSn) 48 weeks
See also
  Status Clinical Trial Phase
Completed NCT02380846 - The Metabolic Effects of Consuming Carbohydrate With Different Protein Types N/A
Completed NCT02402985 - Comparison of a Plant Protein Diet to a Animal Protein Diet Emphasized in Type 2 Diabetics N/A
Not yet recruiting NCT01916603 - Diet, Physical Activity and Breastfeeding Intervention on Maternal Nutrition, Offspring Growth and Development N/A
Completed NCT01616082 - Effect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan II) N/A
Completed NCT01737164 - Effect of Age on Glucose and Lipid Metabolism N/A
Terminated NCT00935766 - Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries Phase 3
Enrolling by invitation NCT00628199 - Study to Create Potential Cell-Based Therapies to Treat Human Disease and Disability
Recruiting NCT04958109 - Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test Phase 1
Completed NCT02275429 - Metabolic Disorders in Ultramarathon Runners During and After the Reunion Island Madmen's Diagonal N/A
Completed NCT01968720 - Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia Phase 2
Completed NCT01719913 - The Effect of Gluten on Gut Microbiome and Metabolic Health. N/A
Completed NCT01708681 - Lean Seafood Intake and Postprandial Metabolism N/A
Completed NCT01705782 - The Effects of Amino Acid Supplement During Acute Inflammation. N/A
Completed NCT01435382 - A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia Phase 1
Recruiting NCT02629926 - Transitional Growth Hormone (GH) Use in Growth Hormone Deficient (GHD) Cancer Survivors Phase 4
Completed NCT00707746 - Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects Phase 2
Completed NCT00550706 - Drug Utilization Prevalence in a Pediatric Care Medical Center N/A
Completed NCT03941392 - Nutritional Study in Spanish Pediatric Population
Terminated NCT02440945 - Use of the DBS for the Follow-up of Blood Clinical Parameters of Old People N/A
Not yet recruiting NCT06000605 - Brain Substrate Switch to Ketones and Lactate N/A